Amarin Corp Plc (AMRN)

[Hondo1021]

I agree that Q1 effects play a role in suppressing refills, but refills should still be a multiple of new scripts. Hopefully, Amarin is running focus groups with patients and doctors to diagnose uptake issues beyond insurance. Don't get me wrong, I'm a huge believer in the science and results but if we get to where new scripts are 1M per week and refills are 1.2 M per week this will be a major problem. I understand that the numbers are not accurate, but the posted numbers indicate some issue. For all our benefit, Amarin needs to address it.